Genmab — Juni 2020

Helge_LarsenPI-redaktør

Genmab før an blandt de danske.

E_L

Ola Landgren on SC-
my prediction based on my clinical experience…is that premedication with steroids can probably be cut back [as well as] the antihistamine premedication. The overall experience with daratumumab will be even more gentle, beyond the fact that it’s now an injection because we can also cut back on the premedication. https://www.targetedonc.com/view/ease-of-use-with-subcutaneous-daratumumab-supplants-the-intravenous-formulation-as-standard-of

E_L

I also think that the use of daratumumab as an extended-dosing regimen in the fashion of a maintenance therapy will probably become more and more popular. It’s not being developed as a maintenance drug, but I think it’s likely that daratumumab could take the role of a continued injection over time.

Helge_LarsenPI-redaktør

Thanks E L.

Helge_LarsenPI-redaktør

Pharma vendt så snuden ned igen.

E_L

Genmab har fået et par ord med på vejen i Jyllands Posten. Det nye partnerskab med Abbvie om midler mod blodkræft udløste en overraskende stor up front-betaling, der vurderes at afspejle, at aftalen er meget ambitiøs, samt at parterne har set meget lovende resultater fra de kliniske forsøg.

AH2005

E L@ Hva' er nu dét, E L? Er du slået over i dansk?

E_L

Helge_LarsenPI-redaktør

Helge_LarsenPI-redaktør

Thanks again E L: https://www.proinvestor.com/index.php?p=debat_1&postid=84861

E_L

BioNTech to Raise USD 250 Million in Private Placement https://www.globenewswire.com/news-release/2020/06/29/2054450/0/en/BioNTech-to-Raise-USD-250-Million-in-Private-Placement.html

E_L

there was some discussion here if BioNTech could finance the PD-L1x4-1BB trials, this could help

Helge_LarsenPI-redaktør

Certainly.

Sukkeralf

Hope to hear whats next from the GEnmab/BioNTech collaboration.....maybe at the CMD in november

GeorgeBest

That is a very good investor BionTech got there!

E_L

could it also be something for ESMO or SITC?

Sukkeralf

Yes the PD-L1/4-1BB could be on those - but I was thinking about the next targets

E_L

ah, ok. the current products are already too many for me to keep a handle on lol . I wonder how many projects Genmab can balance at the same time with all the new staff...

Sukkeralf

Yes that could be a problem - but hopefully they will be good at killing projects also.

Raun

8 C25-aktier over 50% på Styrkebarometer. Genmab i top: 59%

Genmab 59 Chr. Hansen Holding 57 DSV 56 Novozymes B 52 Royal UNIBREW 51 Pandora 51 Novo Nordisk B 51 Bavarian Nordic 51 Ørsted 50 H. Lundbeck 50

Økonomisk Ugebrev (ugebrev.dk)